Esri mapping platform to aid Hy-Vee’s location decisions
REDLANDS, Calif. — Midwestern supermarket chain Hy-Vee is expanding its use of a mapping platform made by geographic information systems firm Esri to aid its real estate decision-making, Esri said Wednesday.
Esri said this would allow Hy-Vee to enhance its site selection, using location analytics that combine demographic and psychographic data.
"We are able to combine data and improve analysis to get a much clearer understanding of new and existing markets," Hy-Vee SVP store development Andy McCann said. "We know how geography plans a significant role in consumers’ choices and behaviors. Using location analytics, we can maximize the way we respond to and understand our customers, stores and market presence."
Merck submits FDA filing for ragweed allergy drug
WHITEHOUSE STATION, N.J. — Drug maker Merck is seeking regulatory approval for an experimental tablet placed under the tongue that could be used to treat ragweed allergies.
Merck said the Food and Drug Administration accepted a regulatory application for its ragweed pollen sublingual allergy immunotherapy tablet. Ragweed, also known as Ambrosia artemisiifolia, is a major cause of seasonal allergies in the United States. Merck also submitted an application for a similar drug, for Timothy grass pollen allergies, in March.
The company expects the FDA to complete its review of both applications in the first half of next year. The drugs work by dissolving under the tongue and treating the underlying cause of allergic rhinitis by generating an immune response.
Healthcare reform law provisions could affect pharmaceutical innovation, Bristol-Myers Squibb exec says
WASHINGTON — Drug maker Bristol-Myers Squibb foresees significant effects on its business from the Patient Protection and Affordable Care Act, company executives told attendees of the its recent shareholder meeting.
In response to a question from a representative of conservative think tank the National Center for Public Policy Research, which is a shareholder in the company, about how the healthcare reform law’s Independent Payments Advisory Board and proposed mandatory drug rebate to the government for "dual eligibles" — patients eligible for Medicare and Medicaid — could affect drug innovation, Bristol U.S. pharmaceuticals division president Giovanni Caforio expressed concern about transparency and public access to medications.
Caforio said Bristol’s management would be "following very closely" developments regarding the board and the law in general, working with industry trade group the Pharmaceutical Research and Manufacturers of America to ensure transparent innovation, continued patient access and support for research and innovation.